Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QoL comparison of trabectedin + pegylated liposomal doxorubicin versus platinum-based combinations in platinum-sensitive recurrent ovarian cancer
2016-005029-36Phase 4Terminated
- Sponsor
- North Eastern German Society of Gynecological Oncology
- Start
- Jul 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of trabectedin, doxorubicin, carboplatin, gemcitabine and paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by North Eastern German Society of Gynecological Oncology. Primary endpoint: Change in quality of life. Started Jul 2017; status: terminated.
02
Drugs
trabectedindoxorubicincarboplatingemcitabinepaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2016-005029-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005029-36.